pirtobrutinib,ibrutinib,venetoclax,bendamustine,rituximab,bortezomib
teva,eli lilly,roche,abbvie,janssen,loxo oncology
['fil,veral,12', 'dlbcl', 'bruin,cll,322', ' ibru', 'pirto', 'bendamustine', 'lymsm', 'bruin', 'venetoclax', 'cll', 'bruin,cll,321', 'ritux', 'roche,(-broche),(-rocheter),(-rochester)']
congress | #ash22
anthony mato, reported updated #cll and #sll results from the bruin study of pirtobrutinib. orr in pts who previously received a btki was 74%. 2% of pts discontinued due to teae. 12mo estimated pfs rate was 68%.
#lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm